Quick Answer
Olema Pharmaceuticals, Inc. reported Research And Development Expense of $157.70 million for the year ending 2025.
- Olema Pharmaceuticals, Inc. showed an increase of +26.6% in Research And Development Expense from 2024 to 2025.
- This data is from Olema Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $795.0 thousand | Q2 2020: $1.95 million | Q3 2020: $4.67 million | Q1 2021: $10.69 million | Q2 2021: $11.91 million | Q3 2021: $12.52 million | Q1 2022: $16.01 million | Q2 2022: $27.05 million | Q3 2022: $17.63 million | Q1 2023: $22.83 million | Q2 2023: $17.99 million | Q3 2023: $19.45 million | Q1 2024: $29.88 million | Q2 2024: $29.11 million | Q3 2024: $33.23 million | Q1 2025: $30.62 million | Q2 2025: $43.90 million | Q3 2025: $39.95 million.
- Over the full 7 years of available data (2019 to 2025), Olema Pharmaceuticals, Inc.'s Research And Development Expense has grown by 3,922.9%.
- Historical annual values: Fiscal year 2025: $157.70 million | Fiscal year 2024: $124.52 million | Fiscal year 2023: $86.14 million | Fiscal year 2022: $82.27 million | Fiscal year 2021: $51.10 million | Fiscal year 2020: $13.70 million | Fiscal year 2019: $3.92 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: